|
© Immunic AG
13.03.2019
2
Cautionary Note Regarding Forward-Looking
Statements
•
Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements
within the meaning of Section
21E of the Securities and Exchange
Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include
statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are
cautioned not to place undue
reliance on them. No
forward-looking statement can be guaranteed, and actual results may differ materially from those projected.
Vital Therapies and Immunic
undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or
otherwise, except to the
extent required by law. We use words
such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,”
“estimates,” “predicts,” “potential,”
“continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be
covered by the safe-harbor provisions of the PSLRA.
•
Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may
differ materially from those
expressed or implied in the
statements due to a number of factors, including, but not limited to, risks relating to the completion of the transaction, including the
need for Vital Therapies stockholder approval and the satisfaction of closing conditions; the anticipated financing to be completed
concurrently with the closing
of the transaction; the cash
balance of the company following the closing of the transaction and the financing, and the expectations with respect thereto; the
business and prospects of the company following the transaction; and the ability of Vital Therapies to remain listed on the Nasdaq
Capital Market. Risks and
uncertainties related to
Immunic
that may cause actual results to differ materially from
those expressed or implied in any forward-looking statement include, but
are not limited to: Immunic’s
plans to develop and commercialize its product candidates, including IMU-838, IMU-935 and IMU-856; the timing of initiation
of
Immunic’s
planned clinical trials; expectations regarding potential market size; the
timing of the availability of data from Immunic’s
clinical
trials; the timing of
any planned investigational new drug
application or new drug application; Immunic’s
plans to
research, develop and commercialize its current and future
product candidates; Immunic’s
ability to successfully collaborate with existing collaborators or enter into
new collaborations, and to fulfill its obligations under
any
such collaboration agreements; the clinical utility, potential benefits and market acceptance of Immunic’s
product candidates; Immunic’s
commercialization,
marketing and manufacturing capabilities and strategy; Immunic’s
ability to identify additional products or product candidates with significant commercial
potential; developments and projections relating to
Immunic’s
competitors and industry; the impact of government
laws and regulations; Immunic’s
ability to
protect its intellectual property position; and Immunic’s
estimates regarding future revenue, expenses, capital requirements and need
for additional financing
following the proposed
transaction.
•
These risks, as well as other risks associated with the transaction, are more
fully discussed in the final proxy statement/prospectus that is included in the
registration statement that was filed by Vital Therapies with the SEC in connection with the proposed transaction.
Additional
risks and uncertainties are identified
and discussed in the “Risk Factors” section of Vital Therapies’
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time
to time with the SEC. Forward-looking statements included in this presentation are based on information available to Vital Therapies
and Immunic
as of the date
of this presentation. Neither Vital Therapies nor Immunic
undertakes any obligation to update such forward-
looking statements to reflect events or
circumstances after the date of this presentation.
|
